{
    "relation": [
        [
            "",
            "PI-Naive",
            "PI-Experienced"
        ],
        [
            "Description",
            "Participants with equal to or less than 1 week of treatment with a Protease Inhibitor (PI)",
            "Participants treated with equal to or less than 3 PIs (any length of time)"
        ]
    ],
    "pageTitle": "A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00040664?sect=Xk015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989826.86/warc/CC-MAIN-20150728002309-00017-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 864919899,
    "recordOffset": 864902785,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups The overall study population consisted of 69 participants presented as \"Overall Fosamprenavir (FPV)/ritonavir (RTV)\" in the Participant Flow section. Furthermore, the Overall FPV/RTV participants are stratified by age cohorts (Arms 2-4). Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details Cohorts were recruited in parallel. All Age Cohorts were given the same treatment. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: ritonavir Drug: fosamprenavir Interventions: HIV Infection Condition: Allocation:\u00a0Non-Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Open\u00a0Label; \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional",
    "textAfterTable": "6-11 Years FPV/RTV Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD), 6-11 years 12-18 Years FPV/RTV Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD), 12-18 years Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Overall Fosamprenavir (FPV)/Ritonavir(RTV) \u00a0 \u00a0 2-5 Years FPV/RTV \u00a0 \u00a0 6-11 Years FPV/RTV \u00a0 \u00a0 12-18 Years FPV/RTV \u00a0 STARTED \u00a0 \u00a0 69 [1] \u00a0 17 \u00a0 \u00a0 17 \u00a0 \u00a0 35 \u00a0 COMPLETED \u00a0 \u00a0 16 \u00a0 \u00a0 4 \u00a0 \u00a0 4 \u00a0 \u00a0 8 \u00a0",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}